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Summary. The cardiovascular nd endocrine profile 
of cromakalim has been studied in 8 healthy men 
(age 25 +_ 2 years; X SEM) and its influence on renin 
release from cultured rat juxtaglomerular cells in 
vitro has also been examined. According to a 
double-blind, randomized sequence the subjects re- 
ceived placebo r cromakalim t mg as a single daily 
oral dose for 5 days. 
Compared to placebo, cromakalim significantly 
increased plasma renin activity (+ 122%; from 1.73 
to 3.87 ng AI-m1-1-h-1), angiotensin II (+105%; 
from 5.1 to 10.5pg.ml-l), and norepinephrine 
(+ 61%) levels, and heart rate (+ 8%). Plasma aldos- 
terone, blood pressure and indices of the electrolyte- 
fluid volume state were unchanged. 
Cromakalim in vitro stimulated renin release, 
from 9.9 to 36.5 ng AI- h-  1.30 min. mg cell protein, 
from juxtaglomerular cells. 
It appears that the presumed K+-channel acti- 
vator cromakalim increases renin release in vivo at 
least in part by direct stimulation of renal juxta- 
glomerular cells. 
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Cromakalim (BRL 34915) is a novel benzopyran 
derivative [1], which has recently been found to pro- 
duce smooth muscle relaxation in vitro by a mecha- 
nism involving cell membrane hyperpolarisation [2]. 
This effect of cromakalim is thought o result from 
its ability to open potassium (K+)-channels, which 
are normally closed at resting membrane potential, 
and to activate the conductance of K+-ions [2-5]. 
Cromakalim has been found to lower blood pressure 
(BP) in animals with certain experimental forms of 
hypertension [6], as well as in hypertensive men [7]. 
The mechanism underlying the cardiovascular re- 
sponse requires further clarification, and the effects 
of cromakalim on catecholamines and the renin- 
angiotensin-aldosterone system have not been eluci- 
dated. Therefore, the first part of the present study 
was undertaken toinvestigate he cardiovascular nd 
endocrine profile of cromakalim in normal humans. 
The major site of renin production, namely, the 
renal juxtaglomerular (JG) cell, is a modified vascu- 
lar smooth muscle cell (VSMC) [8], and its electrical 
properties have been found to be identical with 
VSMC [9]. Experimental evidence suggests that the 
membrane potential of renal JG epitheloid cells is an 
important determinant of renin secretion [10, 11]. 
Considering the hyperpolarizing action of croma- 
kalim on VSCM, the second part of the study was de- 
signed to investigate he influence of cromakalim on 
renin secretion by JG cells in vitro. 
Subjects and methods 
Studies in humans 
Eight healthy non-obese male volunteers, anging in age from 23 
to 27 years (mean (SD), 25 (2) years) were investigated. All had a 
BP consistently below 140/90 mm Hg, none had evidence ofany 
disease, and none was taking any drugs. Written i formed consent 
was obtained from all subjects. 
Cromakalim (Beecham-Wtilfing, FRG), 1 mg, or placebo were 
administered double-blind in randomized sequence, asa single 
oral dose ach morning for 5 days. The subjects consumed a fixed 
diet with a daily intake of 130 meq sodium and 75 meq potassium 
during the 2 study phases, which were separated byan interval of 
3 weeks. Alcohol was avoided. The subjects were instructed to
maintain their usual physical activity. Possible side-effects of 
cromakalim were evaluated by a standard self-administered 
questionnaire, which was completed at the end of each phase. 
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Table 1. Basal values of blood pressure, electrolytes and endo- 
crine variables in normal subjects on placebo and during treat- 
ment with cromakalim 
Variable Placebo Cromakalim 
n 8 
Weight (kg) 63 (2) 63 (2) 
Heart rate, supine 
(beats. rain- 1) 60 (1) 65 a (2) 
Blood pressure, supine 
(mm Hg) 
Systolic t 12 (3) 112 (4) 
Diastolic 65 (2) 63 (2) 
Mean 80 (2) 80 (2) 
Plasma 
Renin activity 
(ngAI .ml - l .h  -1) 1.73 (0.25) 3.87 b (0.36) 
Angiotensin II (pg.ml -~) 5.1 (0.7) 10.5 a (2.3) 
Aldosterone (ng.dl - I) 9.2 (2.0) 8.5 (1.1) 
Adrenaline (ng. dl -  1) 2.47 (0.5) 3.23 (1.00) 
Noradrenaline 
(ng.d1-1) 11.5 (2.0) 18.5 a (2.0) 
Dopamine (ng-d1-1) 0.58 (0.15) 0.64 (0.15) 
irANP (pg- ml- 1) 31 (6) 33 (10) 
Sodium (retool-1 - 1) 140 (0.7) 140 (0.5) 
Potassium (retool-l- I) 4.01 (0.1) 4.00 (0.t) 
Total calcium 
(retool.1-1) 2.28 (0.01) 2.28 (0.01) 
Creatinine (gmol -1- I) 94 (3) 94 (5) 
Urinary sodium 
(mmol.24 h-1 ) 138 (10) 118 (14) 
Urinary potassium 
(mmol. 24 h -  1) 61 (4) 54 (4) 
Creatinine clearance 
(ml. rain- I. 1.73 m - ~) 112 (8) 106 (8) 
Mean (SEM); ap<0.01 vs placebo; bp<0.001 vs placebo 
On Day 4 of each study phase, a 24-h urine sample for deter- 
mination of sodium, potassium and creatinine excretion rates was 
collected, and body weight was recorded. On Day 5, after over- 
night fasting, the last capsule was ingested 2 h prior to the follow- 
ing procedure. After an equilibration period of 1 h in the supine 
position, with a slow intravenous infusion of 5% dextrose solution 
(6 ml/h), basal BP and heart rate (HR) were measured. Blood 
samples were taken from an indwelling cannula inserted 
30-60 rain previously in the arm contralateral to the infusion, for 
determination of plasma renin activity (PRA), angiotensin II 
(ANG II), aldosterone, norepinephrine (NE), epinephrine, dopa- 
mine, immunoreactive atrial natrim-etic peptide (irANP), sodium, 
potassium, calcium and creatinine l vels. The basal samples were 
collected between 08.00 and 08.30 h. The dextrose solution was 
then replaced by a solution of ANG II (Hypertensin CIBA) in 5% 
dextrose, which was infused at approximately 2, 4, and 10 ng- 
kg - 1. rain- 1. During the last 10 rain of each infusion step, BP and 
HR were recorded every min. At the end of each infusion step 
blood was collected from the contralaterat arm for determination 
of PRA, plasma ldosterone, and ANGII. At the last ANGII-infu- 
sion step, blood samples for the determination f plasma irANP, 
sodium and potassium were also collected. 
BP was measured with standard cuff and sphygmomanome- 
ter; the mean of 3 readings was used for analysis. During the infu- 
sion study, BP was monitored with an automatic recorder (Tono- 
print SK Grab, Jungingen, FRG); the mean of 9 to 11 measure- 
merits was used for analysis. Mean arterial BP was calculated as 
the sum of the diastolic and one-third of the pulse pressure. 
Plasma and urinary sodium and potassium were measured by 
flame photometry; calcium and creatinine by Greiner autoana- 
lyser (Greiner SA, Langenthal, Switzerland); PRA, plasma 
ANGII, aldosterone and irANP by radioimmunoassay [12-15] 
and plasma catecholamines by high performance liquid chroma- 
tography with electrochemical detection (Waters, Milford, MA: 
[16]. The methods have been reported previously [17-19]. 
Statistical nalysis was performed with the Statistical Analysis 
System (Version 5,0, Cary, NC, USA). Methods included paired 
(2-tailed) Student's t-test, regression analysis, and analysis of vari- 
ance. Since natural logarithmic transformation rather than abso- 
lute values followed a Gaussian distribution, the natural oga- 
rithms of PRA, ANGII, aldosterone, catecholamine levels and the 
doses of infused ANGII were used for statistical nalysis. 
Studies of juxtaglomerular cell cu#ure in vitro 
Primary cell cultures of rat JG cells were prepared as single cell 
suspensions by perifusion of rat kidneys with citrate, dissociation 
with trypsin and collagenase, and sieving through a22 ~m screen, 
as previously described [20, 21]. The cells were further separated 
on a 25% isoosmotic Percoll gradient, cells with a density of 
1.06 g/ml being used for culture. On the second day of culture, 
about 90% of the attached cells are JG cells, as judged by specific 
immunostaining forrat renin [21]. Renin release from the cells was 
measured as the linear increase in renin activity of the supernatant 
in the absence and presence of cromakalim for 30 rain. The 
culture medium was replaced with prewarmed, Hepes buffer solu- 
tion (132 mM NaC1, 5 mM KCI, 0.8 mM MgSO4, 2 mM CaCI2, 
10 mM sodium acetate, 2 mM NaH2PO4, 10 mM glucose, 20 mM 
Hepes, pH 7.2) and the culture dishes were placed on a heating 
block at 37 ° C. The time-d ependent increase in renin activity in the 
supernatant was then monitored. Renin activity was determined 
by its ability to generate angiotensin I from the plasma of bilate- 
rally nephrectomized rats [211. At the end of the experiments, he 
cells were lysed by addition of 1 N NaOH and cell protein was de- 
termined by the method of Lowry [22]. 
Results 
Studies in humans 
Compared  with p lacebo condit ions,  c romaka l im ad-  
min istered oral ly  over 5 days d id  not  s igni f icant ly 
mod i fy  indices of  the electrolyte-f lu id vo lume state, 
such as body  weight, p lasma sod ium,  potass ium and 
ca lc ium levels, 24-h ur ine sod ium and potass ium ex- 
cret ion rates, or creat in ine c learance (Table 1); BP 
also was unchanged.  However ,  c romaka l im pro-  
duced  a signif icant increase in PRA (+122%,  
p<0.001) ,  p lasma ANGI I  (+105%,  p<0.01) ,  NE  
(+61%,  p<0.01) ,  and  heart  rate (+8%,  p<0.01 ,  
whi le p lasma epinephr ine,  dopamine ,  a ldosterone 
and  i rANP levels were unaltered.  
Dur ing  ANGI I  infus ion and t reatment  either 
with p lacebo or c romaka l im,  the p lasma ANGI I  
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Table 2. Diastolic blood pressure, heart rate and endocrine variables before and during angiotensin II infusion in subjects on placebo and 
after administration f cromakalim 
Placebo Cromakalim 
Pre-infusion Final step Pre-infusion Final step 
n=8 
Diastolic BP (ram Hg) 65 (2) 91 (3) c 63 (2) 88 (1) c 
HR (beats. rain- 1) 60 (1) 59 (4) 65 (2) a 65 (3) e 
Plasma irANP (pg. m1-1) 31 (6) 45 (i1) 33 (10) 48 (10) 
Renin (ng AI. ml-  1 h -  1) t.73 (0.25) 1.36 (0.tl) 3.87 (0.37) r 2.18 (0.13) c
Angiotensin II (pg.m1-1) 5.1 (0.7) 8I (15) e 10.5 (2.3) e 85 (10) c 
Aldosterone(ng-dl ~) 9.2 (2.0) 20 (4) 6 8.5 (1.1) 19.7 (2) c 
Sodium (retool. t - I )  140 (1) 140 (1) 140 (0.5) 140 (1) 
Potassium(mmot-1-1) 4.01 (0.1) 4.16 (0.1) 4.00 (0.1) 4.1 (0.1) 
Mean (SEM); ap<0.05; bp<0.01; Cp<0.001 vs pre-infusion; ap<0.05; ep<0.01; rp<0,001 vs placebo 
30- 
level was correlated with the ANGII infusion rate -~ 
(r=0.81 and r= 0.89, respectively; p< 0.001). The in- ~2o- 
crease in diastolic BP was correlated with the con- ~" 
¢._ 
comitant changes in plasma ANGII level (r=0.76 o 
1 o- and 0.70, respectively; p < 0.001), and so was plasma 
aldosterone (r=0.41 and 0.74, respectively; p<0.05 _v 
to p < 0.001). The plasma ANGII-BP and ANGII-al- <~ 5- 
dosterone response curves (Fig. 1) during ANGII in- 
fusion were not significantly modified by croma- ~ 3 
kalim. The mean values of variables measured 
before and during the final step of the ANGII infu- 
sion are shown in Table 2. The infusion significantly 
(p<0.01) decreased PRA during administration of Fig.1. 
cromakalim, but not during administration ofplace- 
bo (Fig. 2). Plasma irANP tended to increase slightly 
but not significantly during ANGII infusion in both 
phases of the study. 
During administration of cromakalim, 3 subjects 
complained of slight headache. No other symptoms 
were noted. 
Studies of juxtaglomerular cell cultures 
A possible direct effect of cromakalim on renin se- 
cretion was assessed on rat renal JG cells. As shown 
in Fig.3, cromakalim concentration-dependently 
stimulated renin secretion from 9.9 (0.9) to 36.6 
(2.5) ng AI. h-t -30 rain-rag cell protein (SEM, 
n=6, p<0.01). 
Discussion 
The results demonstrate that the presumed K +- 
channel activator and vasorelaxant cromakalim 
1 rag/day for 5 days stimulated the renin-angioten- 
sin system in normal humans and directly activated 
the release of renin from rat JG cells in vitro. 
© 
5 1'0 2'0 5'0 1()0 
Plasma Angiotensin II, pg/ml 
Relationship between plasma angiotensin II and aldo- 
sterone levels before and during angiotensin II infusion on place- 
bo (O) and during administration of cromakalim (@) in 8 men. 
(Mean (SEM); * p< 0.05, ** p< 0.01 vs basal value (by analysis 
of variance) 
Mechanisms which are known to activate the se- 
cretion of renin in humans include an acute fall in 
BP, salt depletion, enhanced sympathetic discharge 
[23], and potassium retention [24]. BP and indices of 
the electrolyte-fluid volume state here were un- 
changed and, therefore, could not account for the 
renin-angiotensin timulation by cromakalim. Circu- 
lating irANP, a potential inhibitor of renin release 
[20, 25], also was unaltered. On the other hand, the 
constellation of increased HR and plasma NE levels 
during cromakalim treatment is consistent with the 
possibility that enhanced sympathetic outflow con- 
tributed at least in part to activation of the renin- 
angiotensin system in vivo. Considering the vasodi- 
lating properties of cromakalim in experimental 
animals [6], its effect on plasma NE and heart rate in 
humans may well be mediated by a baroreflex. 
Since basal plasma aldosterone l vels were un- 
changed or were even slightly decreased in the 
presence of renin-angiotensin stimulation, induced 
by cromakalim the possibility of an inhibitory inter- 
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Fig.2. Relationship between plasma angiotensin II and renin ac- 
tivity before and during angiotensin II infusion on placebo (©) 
and during administration of cromakalim (0) in 8 men. (Mean 
(SEM); * p< 0.01, ** p<0.001 vs basal value (by analysis of vari- 
ance) 
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Effect of cromakalim on renin release from rat juxtaglo- 
merular cell culture. (n=6, Mean (SEM); *p<0.001 vs basal 
value 
action of cromakalim with basal aldosterone secre- 
tion deserves consideration. However, the respon- 
siveness of aldosterone to ANGII was found not to 
be altered uring administration of cromakalim. 
The cromakalim-induced stimulation of renin 
was blunted during acute hyperangiotensinaemia in 
the normal humans. This indicates that the physio- 
logical feedback inhibition of renin release by 
ANGII [261 is not impaired by cromakalim. In fact, 
ANGII infusion during placebo administration, if 
anything, produced a less distinct and statistically in- 
significant decrease in PRA, probably due to the 
lower basal PRA. Previous studies have demon- 
strated that the degree of renin inhibition during 
ANGII infusion depends on the pre-infusion PRA 
level [27]. 
The in vitro study revealed that cromakalim was 
able directly to stimulate JG renin secretion by a 
mechanism independent of the sympathetic nervous 
system. Cromakalim has been found to hyper- 
polarize VSMC by activation of K + channels [2]. 
Renal JG cells are modified VSMC [8] and have 
similar electrical properties to those of typical 
VSMC [9]. Renin release from JG cells is inversely 
related to the intracellular concentration of calcium 
[28]. Indirect evidence suggests that voltage-gated 
calcium channels are involved in the regulation of 
calcium in JG cells [28]. Thus, it is tempting to specu- 
late that the mechanism of cromakalim-induced 
renin secretion may perhaps involve hyperpolarisa- 
tion of JG granular cells. 
Although the exact cellular interactions will have 
to be clarified in future experiments, the in vitro re- 
sults strongly suggest hat a direct action on renal 
juxtaglomerular cells is a likely explanation for the 
effect of cromakalim on renin secretion in vivo. 
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